MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Mirum Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$82.24+2.10 (+2.62%)
Close on Oct 19, 2026
- Market cap
- $5.21B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-4.2%
Net margin
-4.5%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +54.7% | +89.1% | – | – | |
| Free cash flow | +488.0% | – | – | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -68.3% | -8.6% | |
| Return on assets | – | -53.3% | -3.1% | |
| Current ratio | 21.22 | 12.80 | 2.67 | |
| Interest coverage | – | – | -1.5× | |
| Capex to revenue | – | – | 0.2% | |
| Diluted shares | – | 25M | 50M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Mirum Pharmaceuticals generated $389.99M from operations and spent $2.36M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$389.99M
Used
$2.36M
Capital expenditure$2.36M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4.5%
×Asset turnover0.69×
×Equity multiplier2.80×
=Return on equity, FY2025-8.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4.5% | 0.69× | 2.80× | -8.6% |
| FY2024 | -26.1% | 0.51× | 2.78× | -37.1% |
| FY2023 | -87.7% | 0.37× | 2.56× | -83.7% |
| FY2022 | -176.0% | 0.24× | 2.47× | -103.5% |
| FY2021 | -438.9% | 0.07× | 1.83× | -57.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$23.36M
- Cash generatingOperating cash flow above zero$55.83M
- Return on assets improvedROA up on the prior year-13.6% → -3.5%
- Earnings backed by cashOperating cash flow above net income$55.83M vs -$23.36M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.10 → 2.67
- No dilutionShare count did not rise48M → 50M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.52 → 0.78